TRANSFORM STUDY : IMPACT OF DONOR TYPE ON 12-MONTH OUTCOMES OF EVEROLIMUS AND REDUCED CALCINEURIN INHIBITOR VERSUS MYCOPHENOLATE AND STANDARD CALCINEURIN INHIBITOR IN DE NOVO KIDNEY TRANSPLANT PATIENTS